Objetivo The inhibition of DPP IV is a validated target in anti-type II diabetic therapy. Existing inhibitors suffer from poor chemical stability or poor selectivity and will be optimised by substituting an amide group for a fluoroolefin group Ámbito científico medical and health sciencesclinical medicineendocrinologydiabetes Programa(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Tema(s) 1.1.1.-4. - Key action Environment and Health Convocatoria de propuestas Data not available Régimen de financiación RGI - Research grants (individual fellowships) Coordinador UNIVERSITAIRE INSTELLING ANTWERPEN - UNIVERSITEIT ANTWERPEN Aportación de la UE Sin datos Dirección Universiteitsplein 1 2610 WILRIJK (ANTWERPEN) Bélgica Ver en el mapa Coste total Sin datos
